Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
A
• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)
• attention-deficit-hyperactivity-disorder-adhd (5)
B
C
D
• d9-tetrahydrocannabinol-thc (4)
• d9-tetrahydrocannabinolic-acid-thca (1)
E
• endocannabinoid-system-ecs (45)
F
G
• gastrointestinal-disease (6)
H
I
K
L
M
N
• national-institute-on-drug-abuse-nida (1)
• neuro-protective-and-neuro-generative (7)
P
S
T
• traumatic-brain-injury-tbi (1)
• View All (505)Cannabinoid Modulation of Neuroinflammatory Disorders (2011)
Due to their peculiar chemistry, cannabinoids have imposed a challenge on researchers. Cannabinoids have so many benefits that even to date it is impossible to prove or discard each one of them. For now, science aims to understand how cannabinoid compounds are associated with neuroinflammation and how cannabis-based medicine can help millions of patients around the world. The development of safe and effective medicines based on cannabis must overcome the risk of adverse effects. View study
Cannabinoids and multiple sclerosis (2002)
This study shows the increasing amount of evidence indicating that cannabis and individual cannabinoids can be effective in eradicating certain symptoms of multiple sclerosis and spinal cord injuries, including spasticity and pain. View study
Cannabinoids control spasticity and tremor in a multiple sclerosis model (2000)
Cannabis has great therapeutic potential for the control of the symptoms of multiple sclerosis. View study
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial (2003)
This research was based on testing the idea that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis. View study
Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations? (2008)
The medicinal use of cannabis in chronic neurological diseases is a controversial topic of medical research and is a subject of intense public debate. The objective of the present investigation was to evaluate the prevalence of cannabis use, the related factors and the degree of satisfaction in Spanish patients with multiple sclerosis (MS) before the establishment of the use with medical supervision. View study
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study (2004)
Painful muscle spasms are among the most common and distressing symptoms of multiple sclerosis (MS) and have a great influence on the quality of life. In this study the effect of a standardized Cannabis sativa plant extract administered orally is investigated. in patients with (MS) with poorly controlled spasticity. View study
Extract from Cannabis sativa -- Benefit Assessment According to �35a Social Code Book V [Internet] (2012)
Benefits of Cannabis sativa extract in the treatment of patients with spasticity due to multiple sclerosis. View study
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study (2009)
This research focused on studying possible psychopathological symptoms and cognitive deficits, the induction of abuse, as well as the general tolerability and effects on quality of life, fatigue and motor function in patients with multiple sclerosis (MS) with cannabis treated with a cannabis plant extract in free doses (Sativex). View study
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis (2005)
The results of this study provide clear evidence that the use of cannabis is effective in reducing pain and sleep disturbance in patients with central neuropathic pain related to multiple sclerosis. View study
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation ()
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial ()
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms (2016)
The prospective observational mobility improvement study (MOVE) 2 is collecting real-life clinical outcome data in patients with spasticity of multiple sclerosis (MS) resistant to treatment treated with Tetrahydrocannabinol (THC): CBD in orumocosal spray in practice usual clinic. It was concluded that this analysis has been of great benefit, since this provisional analysis has allowed us to better define the place in THC therapy: CBD orumocosal spray within the context of the daily management of our patients with MS spasticity. View study